Amn Healthcare Services
NYSE: AMN
$35.01 ▲ +0.79  (+2.31%)
At close: Jul 17, 2026 · 3:59 PM UTC
Financial Ratios
Market Cap1.29 Bn
P/E-39.84
P/S0.38
Div. Yield0.00
ROIC (Qtr)0.00
Revenue Growth (1y) (Qtr)99.90
Add ratio to table…

About

AMN Healthcare empowers the future of care through one of the nation’s broadest network of highly qualified healthcare professionals. As the leader and innovator in total talent solutions for the healthcare sector in the United States, the company tailors its solutions to clients workforce challenges and goals, and provides staffing, talent optimization strategies, and technology solutions to support caregivers and patient care. The firm’s mission focuses on delivering…

Read more ↓
Sector: Healthcare Industry: Medical Care Facilities CIK: 0001142750

Investment Thesis

▲ Bull case
  • AMN Healthcare is uniquely positioned to capitalize on the structural shift toward total talent solutions, a strategic pivot that the market is underestimating amid its focus on near-term staffing volatility. Management emphasized in the Q&A that client conversations have fundamentally shifted from mere cost-cutting on contract labor to leveraging predictive analytics, internal talent optimization, and tech-enabled workforce planning—areas where AMN’s integrated platform (combining Nurse and Allied, Physician and Leadership, and Technology and Workforce Solutions) offers a defensible moat. This transition is not temporary but reflects a permanent evolution in healthcare workforce management driven by persistent clinician shortages, aging populations, and rising permanent labor costs. The company’s early investments in AI-driven tools like automated candidate scoring in WorkWise, enhanced AMN Passport engagement (with MAUs up >50% YoY), and supplier performance analytics are already yielding tangible efficiency gains, as evidenced by improved fill rates in rapid response deployments and language services margin inflection. These capabilities enable AMN to move beyond commoditized staffing into higher-value, sticky workflow automation and compliance services—segments with significantly better long-term margins and lower cyclicality. The market overlooks how this platform differentiation reduces client churn and increases expansion revenue potential, particularly as AMN accelerates its go-to-market strategy for WorkWise beyond its current base, a move explicitly tied to expected new sales in H2 2026. With leverage already reduced to 1.6x and a strong balance sheet post-labor disruption cash inflows, AMN has the financial flexibility to invest in these growth initiatives without dilutive financing, setting the stage for sustained top-line recovery once underlying demand normalizes—a scenario supported by allied health’s multi-year growth trend and early signs of nurse demand stabilization.
▼ Bear case
  • AMN Healthcare’s near-term profitability is significantly overstated by the market due to its reliance on non-recurring labor disruption revenue, which masked underlying weakness in core segments and created a misleading impression of operational strength that is unlikely to persist. While Q1 FY26 revenue beat expectations at $1.38 billion, $722 million came from labor disruption events—a highly volatile, unpredictable stream that management itself acknowledged is hard to forecast and not expected to recur at similar levels in Q2, where guided revenue plunges to $620–635 million. This stark sequential decline reveals the fragility of the reported results, especially as core Nurse and Allied revenue ex-disruption grew only 8% YoY ($405 million), driven largely by temporary rapid response placements with elevated bill rates that are explicitly not expected to continue. Furthermore, Physician and Leadership Solutions revenue declined 6% YoY to $164 million, with locum tenens volume down 9%, reflecting structural challenges in a segment where clients are shifting to MSP models and third-party channels that AMN fills less efficiently due to lower fill rates—a weakness the company admitted it is trying to fix via tech enablement and added recruiters, but with no clear timeline for success. The Technology and Workforce Solutions segment also continues to deteriorate, with revenue down 15% YoY ($87 million) and language services facing persistent pricing pressure that dragged gross margin down 550 bps YoY, only partially offset by sequential improvements from cost restructuring. These trends suggest AMN’s core businesses are not experiencing organic recovery but are instead being propped up by episodic crisis revenue, while long-term growth initiatives like WorkWise adoption and international nurse pipeline recovery remain contingent on external factors (e.g., Visa retrogression processing at embassies) and internal execution risks that have historically led to delayed turnarounds. The market’s optimism about adjusted EBITDA growing at 2x revenue growth assumes a simultaneous rebound across all segments and successful operational leverage from AI and process changes—yet there is minimal evidence of such leverage materializing today, with SG&A still up YoY and operating margin guidance for Q2 at a concerning -0.6% to +0.1%. Without a clear, sustainable inflection point in demand or margin expansion, AMN risks being valued on peak crisis performance rather than its true, more modest baseline earnings power.

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Care Facilities
S.No. Ticker Company Market CapP/EP/STotal Debt (Qtr)
1 HCA HCA Healthcare, Inc. 87.94 Bn11.251.1548.02 Bn
2 CHE Chemed Corp 18.08 Bn51.687.120.09 Bn
3 THC Tenet Healthcare Corp 16.59 Bn9.740.7713.21 Bn
4 DVA Davita Inc. 15.37 Bn14.021.1010.63 Bn
5 EHC Encompass Health Corp 10.07 Bn654.201.662.57 Bn
6 ENSG Ensign Group, Inc 9.52 Bn27.181.810.14 Bn
7 UHS Universal Health Services Inc 9.19 Bn6.050.524.71 Bn
8 PACS PACS Group, Inc. 6.96 Bn28.551.280.05 Bn